EFG
MRNA icon

Everhart Financial Group’s Moderna MRNA Stock Holding History

Everhart Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,309
Closed -$274K – 326
2024
Q2 		$274K Buy
+2,309
New +$292K 0.07% 234

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Everhart Financial Group's MRNA Position: Q3 2024 in Review

Everhart Financial Group sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,309 shares — an estimated $274K sold.

Everhart Financial Group first reported a position in MRNA in Q2 2024 and held it in 1 quarter. The position peaked at $274K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Everhart Financial Group reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Everhart Financial Group sold 2,309 Moderna shares in Q3 2024, an estimated $274K.
  • Everhart Financial Group first reported a position in Moderna in Q2 2024 and held it in 1 quarter.
  • Everhart Financial Group's Moderna position peaked at $274K in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Everhart Financial Group's 13F filing for Q3 2024, filed 4 Nov 2024.